A single-ascending dose study to investigate the pharmacokinetic and pharmacodynamic profile of subcutaneously injected exendin-9 in Patients with Post-Bariatric Hypoglycemia (PBH)
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Exendin 9 (Primary)
- Indications Hypoglycaemia
- Focus Pharmacokinetics
- Sponsors Eiger BioPharmaceuticals
- 14 Aug 2017 Data published in Diabetes, Obesity and Metabolism, according to an Eiger BioPharmaceuticals media release.
- 13 Jun 2016 According to an Eiger BioPharmaceuticals media release, results from this study were presented at the American Diabetes Association 2016 annual meeting.
- 13 Jun 2016 Results published in the Media Release